These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23346853)

  • 1. The KDIGO anemia guideline: can reason triumph over regulation?
    Wish JB
    Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
    Coyne DW
    Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454
    [No Abstract]   [Full Text] [Related]  

  • 3. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 5. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 7. [Renal anemia treatment and outcome of patients with chronic kidney disease].
    Kuragano T; Nakanishi T
    Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557
    [No Abstract]   [Full Text] [Related]  

  • 8. Anemia in chronic kidney disease: causes, diagnosis, treatment.
    Nurko S
    Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 10. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents.
    McMahon LP; MacGinley R;
    Nephrology (Carlton); 2012 Jan; 17(1):17-9. PubMed ID: 22044720
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 12. Should all patients with chronic kidney disease receive an EPO-type drug?
    Berns JS
    Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
    [No Abstract]   [Full Text] [Related]  

  • 13. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
    Moist LM; Troyanov S; White CT; Wazny LD; Wilson JA; McFarlane P; Harwood L; Sood MM; Soroka SD; Bass A; Manns BJ
    Am J Kidney Dis; 2013 Nov; 62(5):860-73. PubMed ID: 24054466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
    Kliger AS; Foley RN; Goldfarb DS; Goldstein SL; Johansen K; Singh A; Szczech L
    Am J Kidney Dis; 2013 Nov; 62(5):849-59. PubMed ID: 23891356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease anemia management: what should be done?
    Szczech LA
    Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
    Kliger AS; Fishbane S; Finkelstein FO
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESAs in dialysis patients: are you a hedgehog or a fox?
    Singh AK
    J Am Soc Nephrol; 2010 Apr; 21(4):543-6. PubMed ID: 20357173
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.